Meredith Fisher

Meredith Fisher is a Partner with Mass General Brigham Ventures where she focuses on early-stage investments and company creation. Previously, she was Director of Private Investments in the private/family office at Bracebridge Capital where she led investments in early-stage life science companies. She previously led business development for Ginkgo BioWorks, was Senior Director at PureTech Ventures, and was a research scientist at Idenix Pharmaceuticals and Anadys Pharmaceuticals.

Meredith has co-founded multiple MGBV portfolio companies including three as founding CEO. She holds board seats at Brave Bio, Claris Bio, Falcon Therapeutics, FireCyte Therapeutics, Mediar Therapeutics, Violet Therapeutics and Sena Therapeutics. Her previous investments include Amolyt Pharma (sold to AstraZeneca/Alexion – 2024) and Scorpion Therapeutics (sold to Eli Lilly – 2025).  

Meredith holds an undergraduate degree from Mount Holyoke College, an M.B.A. from the MIT Sloan School of Management, and a PhD from Harvard University. While at Harvard, she co-founded Harvard Graduate Women in Science and Engineering (HGWISE).